




RealRate

PHARMACEUTICAL 2019

Oncotelic Therapeutics Inc.
Rank 354 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2019

Oncotelic Therapeutics Inc. Rank 354 of 371

The relative strengths and weaknesses of Oncotelic Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Oncotelic Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 273% points. The greatest weakness of Oncotelic Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 622% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,175%, being 843% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	799
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,161
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	265
Property and Equipment	0
Research and Development	815
Revenues	0
Selling, General and Administrative Expense	2,187

Output Variable	Value in 1000 USD
Assets	799
Liabilities	1,161
Expenses	3,002
Stockholders Equity	-362
Net Income	-2,737
Comprehensive Net Income	-2,737
Economic Capital Ratio	-1,175%

